New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinsons Disease are described. More specifically, the invention relates to methods for treating Parkinsons Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinsons Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
